DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
CAMBRIDGE,England and SAN DIEGO,Jan. 9,2025-- DIOSynVax,a clinical-stage biotechnology company at the forefront of developing innovative,broadly protective vaccines,built on the safety demonstrated by